Diabetes mellitus/chronic kidney disease Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus
Conditions
Interventions
This was a prospective study of patients with T2DM and CKD stage IIIB or IV (estimated glomerular filtration rate MDRD 15 - 44 ml/min/1.73 m^2) selected for treatment with intravenous iron and/or eryt
Sponsors
Hull and East Yorkshire Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with established chronic kidney disease (stage III - IV) (estimated glomerular filtration rate [eGFR] using Modification of Diet in Renal Disease [MDRD] 15 - 59 mL/min/1.73 m^2) who are to undergo iron and/or erythropoiesis stimulating agent (ESA) therapy 2. Patients who have established diabetes mellitus - both type I and II 3. Patients with no prior diagnosis of diabetes mellitus (control group) 4. Aged 18 to 80 years, either sex
Exclusion criteria
Exclusion criteria: 1. Patients who not have renal failure (CKD stage I and II) 2. Patients who are unable or do not wish to give consent 3. Patients with currently investigated for potential blood loss 4. Patients with a haematological malignancy/haemolysis 5. Patients with known haemaglobinopathy 6. Patient with significant liver disease (prothrombin time [PT] greater than 16) 7. Patients with a diagnosis of myeloma 8. Patients with severe hyperparathyroidism (parathyroid hormone [PTH] greater than 800 picograms/ml)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study HbA1c changes in relation to mean blood glucose over study period, measured 1 month before treatment initiation and 4 months after. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured 1 month before treatment initiation and 4 months after: 1. To study HbA1c changes in relation to haemoglobin and haematocrit levels 2. To relate fructosamine, glycated albumin and 1,5 anhydroglucitol with changes in mean blood glucose | — |
Countries
United Kingdom
Outcome results
None listed